Tocilizumab (TCZ) has shown the highest retention rate among biological disease-modifying antirheumatic drugs (bDMARDs) after regression of LPDs in patients with RA, suggesting the usefulness of the anti-interleukin (IL)-6 agents in these patients [6]. This evidence concerns the gene IL6 and rheumatoid arthritis.